Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: Focal cortical dysplasia and glioneuronal tumors

被引:145
作者
Aronica, E
Gorter, JA
Jansen, GH
Van Veelen, CWM
Van Rijen, PC
Leenstra, S
Ramkema, M
Scheffer, GL
Scheper, RJ
Troost, D
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Neuropathol, NL-1105 AZ Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Acad Hosp, Dept Pathol, Amsterdam, Netherlands
[3] Univ Utrecht, Med Ctr, Dept Neurosurg, Utrecht, Netherlands
[4] Ottawa Gen Hosp, Dept Neuropathol, Ottawa, ON K1H 8L6, Canada
[5] Univ Amsterdam, Swammerdam Inst Life Sci, Amsterdam, Netherlands
[6] Stichting Epilepsie Nederland, Heemstede, Netherlands
[7] Univ Amsterdam, Acad Med Ctr, Dept Neurosurg, NL-1105 AZ Amsterdam, Netherlands
关键词
P-glycoprotein; multidrug resistance-associated protein; ganglioglioma; pediatric epilepsy; balloon cells; blood vessels;
D O I
10.1016/S0306-4522(02)00992-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The cell-specific distribution of multidrug resistance extrusion pumps was studied in developmental glioneuronal lesions, including focal cortical dysplasia (15 cases) and ganglioglioma (15 cases) from patients with medically intractable epilepsy. Lesional, perilesional, as well as normal brain regions were examined for the expression of the multidrug resistance gene 1 encoded P-glycoprotein (P-gp) and the multidrug resistance-associated protein 1 (MRP1) by immunocytochemistry. In normal brain MRP1 expression was below detection, whereas P-gp staining was present only in blood vessels. MRP1 and P-gp immunoreactivity was observed in dysplastic neurons of 11/15 cases of focal cortical dysplasia, as well as in the neuronal component of 14/15 ganglioglioma. Glial cells with astrocytic morphology within the lesion showed multidrug-resistant protein immunoreactivity (P-gp>MRP1). Moderate to strong MRP1 and P-gp immunoreactivity was observed in a population of large ballooned neuroglial cells. P-gp appeared to be most frequently expressed in glial fibrillary acidic protein-positive balloon cells (glial type), whereas MRP1 was more frequently expressed in microtubule-associated protein 2-positive balloon cells (neuronal type). In both types of lesions strong P-gp immunoreactivity was found in lesional vessels. Perilesional regions did not show increased staining in vessels or in neuronal cells compared with normal cortex. The predominant intralesional cell-specific distribution of multidrug transporter proteins supports the hypothesis of a constitutive overexpression as common mechanism underlying the intrinsic pharmaco-resistance to antiepileptic drugs of both malformative and neoplastic glioneuronal developmental lesions. (C) 2003 IBRO. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:417 / 429
页数:13
相关论文
共 72 条
  • [1] Abbott N Joan, 2002, Novartis Found Symp, V243, P38
  • [2] [Anonymous], 1987, Surgical Treatment of the Epilepsies
  • [3] Arancia G, 2001, MARC MALPIG SYMP SER, V7, P59
  • [4] Aronica E, 2001, ACTA NEUROPATHOL, V101, P383
  • [5] Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy
    Aronica, E
    Yankaya, B
    Jansen, GH
    Leenstra, S
    van Veelen, CWM
    Gorter, JA
    Troost, D
    [J]. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2001, 27 (03) : 223 - 237
  • [6] Aronica E, 2001, ACTA NEUROPATHOL, V101, P449
  • [7] Glioneuronal tumors and medically intractable epilepsy: a clinical study with long-term follow-up of seizure outcome after surgery
    Aronica, E
    Leenstra, S
    van Veelen, CWM
    van Rijen, PC
    Hulsebos, TJ
    Tersmette, AC
    Yankaya, B
    Troost, D
    [J]. EPILEPSY RESEARCH, 2001, 43 (03) : 179 - 191
  • [8] Upregulation of metabotropic glutamate receptor subtype mGluR3 and mGluR5 in reactive astrocytes in a rat model of mesial temporal lobe epilepsy
    Aronica, E
    van Vliet, EA
    Mayboroda, OA
    Troost, D
    da Silva, FHL
    Gorter, JA
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 (07) : 2333 - 2344
  • [9] Aszalos A, 1998, ANTICANCER RES, V18, P2937
  • [10] Blümcke I, 2002, J NEUROPATH EXP NEUR, V61, P575